Samsung Biologics has obtained additional ISO22301 certification, an international standard for business continuity management system for its third plant, from the British Standard Institute (BSI), a global certification body, a company spokesman said on May 19.
Samsung Biologics received the ISO22301 certificate from BSI and the British Embassy in Seoul at the ceremony held at its headquarters in Songdo, Incheon, on May 19.
ISO22301 is the International Standard set by the International Organization for Standardization (ISO) to minimize the suspension of business by enterprises due to serious accidents.
Samsung Biologics acquired ISO22301 for the first and second plants and some support functions from BSI in April 2018.
Along with its third plant, which began operation in October 2018, the certification was made additionally for bio-safety testing service lab (BTS) and small contract manufacturing organization (sCMO).
Samsung Biologics' third plant is the world's largest biopharmaceutical production plant based on a single plant equipped with 180,000 liters of production facilities and advanced technologies such as "N-1 Perfusion."
Samsung Biologics began building a business continuity management system for its third plant, other than the existing one and two plants, to enhance trust in its customers since last year.
To that end, a task force consisting of a total of 39 people from 32 departments was created to check all possible risks, conduct virtual training. Accordingly, It has perfectly established processes for prevention of crisis situations and rapid recovery.
Samsung Biologics, in particular, received high praise from the BSI for its enterprise-wide response system to the global pandemic, COVID-19, and real-time communication with customers.
With the additional certification, Samsung Biologics will be able to secure more trust from global customers in recognition of its stable product production and crisis response capabilities of its all production facilities.
Samsung Biologics CEO Kim Tae-han said, "As the products of our customers are directly related to the precious lives of patients, we should be able to ensure stable supply and demand in any crisis. We will be recognized as the most trusted partner by our customers through the acquisition of ISO22301 and will do our best to enhance business competitiveness through quality orders."
